333 SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN